Literature DB >> 22315164

Matching mice to malignancy: molecular subgroups and models of medulloblastoma.

Jasmine Lau1, Christin Schmidt, Shirley L Markant, Michael D Taylor, Robert J Wechsler-Reya, William A Weiss.   

Abstract

INTRODUCTION: Medulloblastoma, the largest group of embryonal brain tumors, has historically been classified into five variants based on histopathology. More recently, epigenetic and transcriptional analyses of primary tumors have subclassified medulloblastoma into four to six subgroups, most of which are incongruous with histopathological classification. DISCUSSION: Improved stratification is required for prognosis and development of targeted treatment strategies, to maximize cure and minimize adverse effects. Several mouse models of medulloblastoma have contributed both to an improved understanding of progression and to developmental therapeutics. In this review, we summarize the classification of human medulloblastoma subtypes based on histopathology and molecular features. We describe existing genetically engineered mouse models, compare these to human disease, and discuss the utility of mouse models for developmental therapeutics. Just as accurate knowledge of the correct molecular subtype of medulloblastoma is critical to the development of targeted therapy in patients, we propose that accurate modeling of each subtype of medulloblastoma in mice will be necessary for preclinical evaluation and optimization of those targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315164      PMCID: PMC3515664          DOI: 10.1007/s00381-012-1704-1

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  129 in total

1.  Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2.

Authors:  Olga Shakhova; Carly Leung; Erwin van Montfort; Anton Berns; Silvia Marino
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

2.  Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Authors:  Silvia Buonamici; Juliet Williams; Michael Morrissey; Anlai Wang; Ribo Guo; Anthony Vattay; Kathy Hsiao; Jing Yuan; John Green; Beatriz Ospina; Qunyan Yu; Lance Ostrom; Paul Fordjour; Dustin L Anderson; John E Monahan; Joseph F Kelleher; Stefan Peukert; Shifeng Pan; Xu Wu; Sauveur-Michel Maira; Carlos García-Echeverría; Kimberly J Briggs; D Neil Watkins; Yung-mae Yao; Christoph Lengauer; Markus Warmuth; William R Sellers; Marion Dorsch
Journal:  Sci Transl Med       Date:  2010-09-29       Impact factor: 17.956

3.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

4.  Altered neural cell fates and medulloblastoma in mouse patched mutants.

Authors:  L V Goodrich; L Milenković; K M Higgins; M P Scott
Journal:  Science       Date:  1997-08-22       Impact factor: 47.728

5.  GDC-0449-a potent inhibitor of the hedgehog pathway.

Authors:  Kirk D Robarge; Shirley A Brunton; Georgette M Castanedo; Yong Cui; Michael S Dina; Richard Goldsmith; Stephen E Gould; Oivin Guichert; Janet L Gunzner; Jason Halladay; Wei Jia; Cyrus Khojasteh; Michael F T Koehler; Karen Kotkow; Hank La; Rebecca L Lalonde; Kevin Lau; Leslie Lee; Derek Marshall; James C Marsters; Lesley J Murray; Changgeng Qian; Lee L Rubin; Laurent Salphati; Mark S Stanley; John H A Stibbard; Daniel P Sutherlin; Savita Ubhayaker; Shumei Wang; Susan Wong; Minli Xie
Journal:  Bioorg Med Chem Lett       Date:  2009-08-15       Impact factor: 2.823

6.  Health and persistent functional late effects in adult survivors of childhood CNS tumours: a population-based cohort study.

Authors:  K K Boman; E Hovén; M Anclair; B Lannering; G Gustafsson
Journal:  Eur J Cancer       Date:  2009-07-16       Impact factor: 9.162

Review 7.  The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.

Authors:  Barry L Pizer; Steven C Clifford
Journal:  Br J Neurosurg       Date:  2009-08       Impact factor: 1.596

8.  Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome.

Authors:  H Hahn; C Wicking; P G Zaphiropoulous; M R Gailani; S Shanley; A Chidambaram; I Vorechovsky; E Holmberg; A B Unden; S Gillies; K Negus; I Smyth; C Pressman; D J Leffell; B Gerrard; A M Goldstein; M Dean; R Toftgard; G Chenevix-Trench; B Wainwright; A E Bale
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

9.  Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure.

Authors:  Hiromichi Kimura; Jessica M Y Ng; Tom Curran
Journal:  Cancer Cell       Date:  2008-03       Impact factor: 31.743

10.  Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice.

Authors:  Todd D McCall; Carolyn A Pedone; Daniel W Fults
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

View more
  11 in total

1.  Epigenetic states of cells of origin and tumor evolution drive tumor-initiating cell phenotype and tumor heterogeneity.

Authors:  Kin-Hoe Chow; Dong-Mi Shin; Molly H Jenkins; Emily E Miller; David J Shih; Seungbum Choi; Benjamin E Low; Vivek Philip; Brad Rybinski; Roderick T Bronson; Michael D Taylor; Kyuson Yun
Journal:  Cancer Res       Date:  2014-08-18       Impact factor: 12.701

2.  Development and characterization of murine models of medulloblastoma extraneural growth in bone.

Authors:  Jessica M Grunda; Dezhi Wang; Gregory A Clines
Journal:  Clin Exp Metastasis       Date:  2013-03-15       Impact factor: 5.150

Review 3.  Contemporary murine models in preclinical astrocytoma drug development.

Authors:  Robert S McNeill; Mark Vitucci; Jing Wu; C Ryan Miller
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

4.  BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation.

Authors:  Dan Zhu; Satoru Osuka; Zhaobin Zhang; Zachery R Reichert; Liquan Yang; Yonehiro Kanemura; Ying Jiang; Shuo You; Hanwen Zhang; Narra S Devi; Debanjan Bhattacharya; Shingo Takano; G Yancey Gillespie; Tobey Macdonald; Chalet Tan; Ryo Nishikawa; William G Nelson; Jeffrey J Olson; Erwin G Van Meir
Journal:  Cancer Cell       Date:  2018-06-11       Impact factor: 31.743

Review 5.  Molecular subgroups of medulloblastoma.

Authors:  Paul A Northcott; Adrian M Dubuc; Stefan Pfister; Michael D Taylor
Journal:  Expert Rev Neurother       Date:  2012-07       Impact factor: 4.618

6.  MEMRI-based imaging pipeline for guiding preclinical studies in mouse models of sporadic medulloblastoma.

Authors:  Harikrishna Rallapalli; I-Li Tan; Eugenia Volkova; Alexandre Wojcinski; Benjamin C Darwin; Jason P Lerch; Alexandra L Joyner; Daniel H Turnbull
Journal:  Magn Reson Med       Date:  2019-08-12       Impact factor: 4.668

7.  In vivo Mn-enhanced MRI for early tumor detection and growth rate analysis in a mouse medulloblastoma model.

Authors:  Giselle A Suero-Abreu; G Praveen Raju; Orlando Aristizábal; Eugenia Volkova; Alexandre Wojcinski; Edward J Houston; Diane Pham; Kamila U Szulc; Daniel Colon; Alexandra L Joyner; Daniel H Turnbull
Journal:  Neoplasia       Date:  2014-12       Impact factor: 5.715

8.  ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma.

Authors:  Wendy J Ingram; Lisa M Crowther; Erica B Little; Ruth Freeman; Ivon Harliwong; Desi Veleva; Timothy E Hassall; Marc Remke; Michael D Taylor; Andrew R Hallahan
Journal:  Exp Hematol Oncol       Date:  2013-10-04

Review 9.  Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas.

Authors:  Rintaro Hashizume; Nalin Gupta
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 10.  Medulloblastoma in the Molecular Era.

Authors:  Claudia Miranda Kuzan-Fischer; Kyle Juraschka; Michael D Taylor
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.